Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

The past two months have been tough for Bris­tol My­ers Squibb and its check­point in­hibitor Op­di­vo af­ter set­backs in lung and brain can­cers. But in the bat­tle against Mer­ck’s Keytru­da, any suc­cess mat­ters — and now Bris­tol could be look­ing at a quick ap­proval for Op­di­vo in an un­matched in­di­ca­tion.

The FDA will launch a speedy re­view of a com­bi­na­tion of Bris­tol My­ers Squibb’s Op­di­vo and chemother­a­py to treat first-line pa­tients with ad­vanced or metasta­t­ic gas­tric can­cer, gas­troe­sophageal junc­tion can­cer or esophageal ade­no­car­ci­no­ma, the drug­mak­er said Wednes­day. The agency set an ac­tion date of May 25 for the ap­pli­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.